遗传性血管性水肿治疗市场 - 全球产业规模、份额、趋势、机会和预测，按药物类别、配销通路、应用、地区和竞争细分，2020-2030 年预测

2024 年全球遗传性血管性水肿治疗市场价值为 43.6 亿美元，预计到 2030 年将达到 72.8 亿美元，复合年增长率为 8.89%。全球遗传性血管性水肿治疗市场正在经历显着扩张，这得益于人们认识的提高、诊断能力的提高以及新治疗方案的推出。基因研究的进步使得早期和准确的诊断成为可能，从而可以及时干预和更好地管理疾病。製药公司正专注于开发标靶疗法，包括单株抗体和小分子抑制剂，以提供长期预防和急性治疗解决方案。遗传性血管性水肿盛行率的不断上升，加上医疗支出的不断增加和患者权益保护的不断加强，进一步推动了市场的成长。此外，创新疗法的监管批准以及皮下和口服治疗方案的出现正在提高患者的依从性和便利性，为该行业创造了良好的前景。

强大的新药通路和不断增加的研发投入正在塑造竞争格​​局。生物製药公司正在探索具有更高疗效、更少副作用和改进给药方法的下一代疗法。从静脉注射到皮下和口服治疗的转变正在改变护理标准，减轻患者和医疗保健提供者的负担。製药公司、研究机构和患者组织之间的合作和策略伙伴关係正在加速药物开发和市场渗透。随着越来越多的患者寻求预防措施而不是仅依赖急性治疗，预防性治疗的扩展预计将推动长期市场永续性。

主要市场驱动因素

研发方面的进步

主要市场挑战

治疗费用高昂

主要市场趋势

个人化医疗方法

目录

第 1 章：产品概述

第 2 章：研究方法

第 3 章：执行摘要

第 4 章：全球遗传性血管性水肿治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 依药物类别（C1 酯酶抑制剂、选择性缓激肽 B2 受体拮抗剂、激肽释放酶抑制剂、其他药物类别）
  • 按配销通路划分（医院药房、零售药房、其他分销管道）
  • 依用途（预防、按需）
  • 按地区
  • 按公司分类（2024）
• 市场地图
  • 按药物类别
  • 按配销通路
  • 按应用
  • 按地区

第 5 章：亚太地区遗传性血管性水肿治疗市场展望

• 市场规模和预测
  • 按价值
• 市场占有率和预测
  • 按药物类别
  • 按配销通路
  • 按应用
  • 按国家
• 亚太地区：国家分析
  • 中国
  • 印度
  • 澳洲
  • 日本
  • 韩国

第 6 章：欧洲遗传性血管性水肿治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 欧洲：国家分析
  • 德国
  • 西班牙
  • 义大利
  • 英国

第 7 章：北美遗传性血管性水肿治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 北美：国家分析
  • 墨西哥
  • 加拿大

第 8 章：南美洲遗传性血管性水肿治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• 南美洲：国家分析
  • 阿根廷
  • 哥伦比亚

第 9 章：中东和非洲遗传性血管性水肿治疗市场展望

• 市场规模和预测
• 市场占有率和预测
• MEA：国家分析
  • 沙乌地阿拉伯
  • 阿联酋

第 10 章：市场动态

• 驱动程式
• 挑战

第 11 章：市场趋势与发展

• 最新动态
• 产品发布
• 合併与收购

第 12 章：全球遗传性血管性水肿治疗市场：SWOT 分析

第 13 章：波特五力分析

• 产业竞争
• 新进入者的潜力
• 供应商的力量
• 顾客的力量
• 替代产品的威胁

第 14 章：竞争格局

• Shire plc
• Sanofi SA
• Pharming Healthcare Inc.
• Attune Pharmaceuticals
• Adverum Biotechnologies
• Arrowhead Pharmaceuticals
• Ionis Pharmaceuticals
• BioCryst Pharmaceuticals Inc.
• CSL Behring.
• CENTOGENE NV

第 15 章：策略建议

第16章调查会社について・免责事项

Global Hereditary Angioedema Therapeutics Market was valued at USD 4.36 Billion in 2024 and is expected to reach USD 7.28 Billion in the forecast period with a CAGR of 8.89% through 2030. The global hereditary angioedema therapeutics market is experiencing significant expansion, driven by increasing awareness, improved diagnostic capabilities, and the introduction of novel treatment options. Advances in genetic research have enabled early and accurate diagnosis, allowing for timely intervention and better disease management. Pharmaceutical companies are focusing on developing targeted therapies, including monoclonal antibodies and small-molecule inhibitors, to provide long-term prophylaxis and acute treatment solutions. The growing prevalence of hereditary angioedema, coupled with rising healthcare expenditure and patient advocacy efforts, is further supporting market growth. Furthermore, regulatory approvals for innovative therapies and the emergence of subcutaneous and oral treatment options are enhancing patient adherence and convenience, creating a favorable outlook for the industry.

A strong pipeline of novel drugs and increased investment in research and development are shaping the competitive landscape. Biopharmaceutical companies are exploring next-generation therapies that offer enhanced efficacy, fewer side effects, and improved administration methods. The shift from intravenous to subcutaneous and oral treatments is transforming the standard of care, reducing the burden on patients and healthcare providers. Collaborations and strategic partnerships between pharmaceutical firms, research institutions, and patient organizations are accelerating drug development and market penetration. The expansion of prophylactic treatments is expected to drive long-term market sustainability, as more patients seek preventive measures rather than relying solely on acute treatments.

Key Market Drivers

Advancements in Research and Development (R&D)

Advancements in Research and Development (R&D) have been pivotal in boosting the Global Hereditary Angioedema Therapeutics Market. Hereditary Angioedema is a rare genetic disorder characterized by debilitating and unpredictable swelling episodes that can be life-threatening. In recent years, the relentless pursuit of scientific knowledge and innovative therapies has transformed the landscape of HAE treatment.

One of the most significant drivers of market growth has been the breakthrough discoveries in understanding the underlying mechanisms of HAE. Researchers have delved deep into the genetic and biochemical aspects of the disease, leading to a more precise understanding of how it develops and progresses. This increased knowledge has paved the way for the development of targeted therapies that are specifically designed to address the root causes of HAE.

Monoclonal antibodies, in particular, have emerged as a revolutionary approach in HAE therapeutics. These monoclonal antibodies, such as lanadelumab and ecallantide, have been engineered to specifically inhibit the activity of proteins like plasma kallikrein, which play a critical role in HAE attacks. This precision in drug design has proven highly effective in preventing and managing HAE episodes, providing patients with newfound hope and relief from the burden of their condition.

Key Market Challenges

High Treatment Costs

The High treatment costs have emerged as a significant obstacle hindering the growth and accessibility of the Global Hereditary Angioedema Therapeutics Market. HAE is a rare genetic disorder characterized by recurrent and potentially life-threatening swelling episodes. While advancements in therapeutics have improved the quality of life for HAE patients, the exorbitant cost of these treatments poses a considerable challenge. The prohibitively high cost of treatment makes these life-saving therapies inaccessible to a substantial portion of HAE patients, especially those without comprehensive health insurance coverage. This leads to disparities in access to care, with only a fraction of those in need benefiting from the latest advancements in HAE therapeutics.

For individuals who manage to access HAE therapies, the financial strain can be overwhelming. Copayments, deductibles, and out-of-pocket expenses can quickly accumulate, potentially forcing patients to make difficult choices between their healthcare needs and other essential expenses.

Access to HAE treatments is even more challenging in regions with limited healthcare resources and lower income levels. This exacerbates global healthcare disparities, where patients in wealthier nations have greater access to cutting-edge treatments, while those in less affluent regions struggle to secure even basic care.

Key Market Trends

Personalized Medicine Approaches

Hereditary angioedema (HAE) is a rare genetic disorder characterized by recurrent episodes of severe swelling in various body parts, including the extremities, face, gastrointestinal tract, and airway. This condition is caused by mutations in the SERPING1 gene, leading to deficient or dysfunctional C1 inhibitor (C1-INH) proteins, which play a crucial role in regulating inflammatory pathways.

Personalized medicine has significantly advanced the management of HAE by tailoring treatments to individual genetic profiles and disease manifestations. The process begins with precise genetic testing to identify specific mutations in the SERPING1 gene, which helps determine the subtype of HAE a patient has. This accurate diagnosis is essential, as it guides the selection of targeted therapies that address the underlying pathophysiological mechanisms.

For instance, patients with Type I HAE, characterized by low levels of functional C1-INH, may benefit from C1-INH replacement therapies such as Berinert or Cinryze. These treatments work by supplementing the deficient protein, thereby preventing or reducing the frequency of swelling episodes. Conversely, patients with normal C1-INH levels but dysfunctional protein (Type II HAE) might respond better to therapies that inhibit the kallikrein-kinin pathway, such as lanadelumab (Takhzyro), a monoclonal antibody that targets plasma kallikrein to prevent bradykinin formation, a key mediator of swelling in HAE.

Key Market Players

• Shire plc
• Sanofi SA
• Pharming Healthcare Inc.
• Attune Pharmaceuticals
• Adverum Biotechnologies
• Arrowhead Pharmaceuticals
• Ionis Pharmaceuticals
• BioCryst Pharmaceuticals Inc.
• CSL Behring.
• CENTOGENE N.V

Report Scope:

In this report, the Global Hereditary Angioedema Therapeutics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Hereditary Angioedema Therapeutics Market, By Drug Class:

• C1 Esterase Inhibitor
• Selective Bradykinin B2 Receptor Antagonist
• Kallikrein Inhibitor
• Other Drug Classes

Hereditary Angioedema Therapeutics Market, By Distribution Channel:

• Hospital Pharmacy
• Retail Pharmacy
• Other Distribution Channels

Hereditary Angioedema Therapeutics Market, By Application:

• Prophylaxis
• On-demand

Hereditary Angioedema Therapeutics Market, By Region:

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Hereditary Angioedema Therapeutics Market.

Available Customizations:

Global Hereditary Angioedema Therapeutics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Hereditary Angioedema Therapeutics Market Outlook

• 4.1. Market Size & Forecast
  • 4.1.1. By Value
• 4.2. Market Share & Forecast
  • 4.2.1. By Drug Class (C1 Esterase Inhibitor, Selective Bradykinin B2 Receptor Antagonist, Kallikrein Inhibitor, Other Drug Classes)
  • 4.2.2. By Distribution Channel (Hospital Pharmacy, Retail Pharmacy, Other Distribution Channels)
  • 4.2.3. By Application (Prophylaxis, On-demand)
  • 4.2.4. By Region
  • 4.2.5. By Company (2024)
• 4.3. Market Map
  • 4.3.1. By Drug Class
  • 4.3.2. By Distribution Channel
  • 4.3.3. By Application
  • 4.3.4. By Region

5. Asia Pacific Hereditary Angioedema Therapeutics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Drug Class
  • 5.2.2. By Distribution Channel
  • 5.2.3. By Application
  • 5.2.4. By Country
• 5.3. Asia Pacific: Country Analysis
  • 5.3.1. China Hereditary Angioedema Therapeutics Market Outlook
    • 5.3.1.1. Market Size & Forecast
      • 5.3.1.1.1. By Value
    • 5.3.1.2. Market Share & Forecast
      • 5.3.1.2.1. By Drug Class
      • 5.3.1.2.2. By Distribution Channel
      • 5.3.1.2.3. By Application
  • 5.3.2. India Hereditary Angioedema Therapeutics Market Outlook
    • 5.3.2.1. Market Size & Forecast
      • 5.3.2.1.1. By Value
    • 5.3.2.2. Market Share & Forecast
      • 5.3.2.2.1. By Drug Class
      • 5.3.2.2.2. By Distribution Channel
      • 5.3.2.2.3. By Application
  • 5.3.3. Australia Hereditary Angioedema Therapeutics Market Outlook
    • 5.3.3.1. Market Size & Forecast
      • 5.3.3.1.1. By Value
    • 5.3.3.2. Market Share & Forecast
      • 5.3.3.2.1. By Drug Class
      • 5.3.3.2.2. By Distribution Channel
      • 5.3.3.2.3. By Application
  • 5.3.4. Japan Hereditary Angioedema Therapeutics Market Outlook
    • 5.3.4.1. Market Size & Forecast
      • 5.3.4.1.1. By Value
    • 5.3.4.2. Market Share & Forecast
      • 5.3.4.2.1. By Drug Class
      • 5.3.4.2.2. By Distribution Channel
      • 5.3.4.2.3. By Application
  • 5.3.5. South Korea Hereditary Angioedema Therapeutics Market Outlook
    • 5.3.5.1. Market Size & Forecast
      • 5.3.5.1.1. By Value
    • 5.3.5.2. Market Share & Forecast
      • 5.3.5.2.1. By Drug Class
      • 5.3.5.2.2. By Distribution Channel
      • 5.3.5.2.3. By Application

6. Europe Hereditary Angioedema Therapeutics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Drug Class
  • 6.2.2. By Distribution Channel
  • 6.2.3. By Application
  • 6.2.4. By Country
• 6.3. Europe: Country Analysis
  • 6.3.1. France Hereditary Angioedema Therapeutics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Drug Class
      • 6.3.1.2.2. By Distribution Channel
      • 6.3.1.2.3. By Application
  • 6.3.2. Germany Hereditary Angioedema Therapeutics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Drug Class
      • 6.3.2.2.2. By Distribution Channel
      • 6.3.2.2.3. By Application
  • 6.3.3. Spain Hereditary Angioedema Therapeutics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Drug Class
      • 6.3.3.2.2. By Distribution Channel
      • 6.3.3.2.3. By Application
  • 6.3.4. Italy Hereditary Angioedema Therapeutics Market Outlook
    • 6.3.4.1. Market Size & Forecast
      • 6.3.4.1.1. By Value
    • 6.3.4.2. Market Share & Forecast
      • 6.3.4.2.1. By Drug Class
      • 6.3.4.2.2. By Distribution Channel
      • 6.3.4.2.3. By Application
  • 6.3.5. United Kingdom Hereditary Angioedema Therapeutics Market Outlook
    • 6.3.5.1. Market Size & Forecast
      • 6.3.5.1.1. By Value
    • 6.3.5.2. Market Share & Forecast
      • 6.3.5.2.1. By Drug Class
      • 6.3.5.2.2. By Distribution Channel
      • 6.3.5.2.3. By Application

7. North America Hereditary Angioedema Therapeutics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Drug Class
  • 7.2.2. By Distribution Channel
  • 7.2.3. By Application
  • 7.2.4. By Country
• 7.3. North America: Country Analysis
  • 7.3.1. United States Hereditary Angioedema Therapeutics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Drug Class
      • 7.3.1.2.2. By Distribution Channel
      • 7.3.1.2.3. By Application
  • 7.3.2. Mexico Hereditary Angioedema Therapeutics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Drug Class
      • 7.3.2.2.2. By Distribution Channel
      • 7.3.2.2.3. By Application
  • 7.3.3. Canada Hereditary Angioedema Therapeutics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Drug Class
      • 7.3.3.2.2. By Distribution Channel
      • 7.3.3.2.3. By Application

8. South America Hereditary Angioedema Therapeutics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Drug Class
  • 8.2.2. By Distribution Channel
  • 8.2.3. By Application
  • 8.2.4. By Country
• 8.3. South America: Country Analysis
  • 8.3.1. Brazil Hereditary Angioedema Therapeutics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Drug Class
      • 8.3.1.2.2. By Distribution Channel
      • 8.3.1.2.3. By Application
  • 8.3.2. Argentina Hereditary Angioedema Therapeutics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Drug Class
      • 8.3.2.2.2. By Distribution Channel
      • 8.3.2.2.3. By Application
  • 8.3.3. Colombia Hereditary Angioedema Therapeutics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Drug Class
      • 8.3.3.2.2. By Distribution Channel
      • 8.3.3.2.3. By Application

9. Middle East and Africa Hereditary Angioedema Therapeutics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Drug Class
  • 9.2.2. By Distribution Channel
  • 9.2.3. By Application
  • 9.2.4. By Country
• 9.3. MEA: Country Analysis
  • 9.3.1. South Africa Hereditary Angioedema Therapeutics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Drug Class
      • 9.3.1.2.2. By Distribution Channel
      • 9.3.1.2.3. By Application
  • 9.3.2. Saudi Arabia Hereditary Angioedema Therapeutics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Drug Class
      • 9.3.2.2.2. By Distribution Channel
      • 9.3.2.2.3. By Application
  • 9.3.3. UAE Hereditary Angioedema Therapeutics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Drug Class
      • 9.3.3.2.2. By Distribution Channel
      • 9.3.3.2.3. By Application

10. Market Dynamics

• 10.1. Drivers
• 10.2. Challenges

11. Market Trends & Developments

• 11.1. Recent Developments
• 11.2. Product Launches
• 11.3. Mergers & Acquisitions

12. Global Hereditary Angioedema Therapeutics Market: SWOT Analysis

13. Porter's Five Forces Analysis

• 13.1. Competition in the Industry
• 13.2. Potential of New Entrants
• 13.3. Power of Suppliers
• 13.4. Power of Customers
• 13.5. Threat of Substitute Product

14. Competitive Landscape

• 14.1. Shire plc
  • 14.1.1. Business Overview
  • 14.1.2. Company Snapshot
  • 14.1.3. Products & Services
  • 14.1.4. Current Capacity Analysis
  • 14.1.5. Financials (In case of listed)
  • 14.1.6. Recent Developments
  • 14.1.7. SWOT Analysis
• 14.2. Sanofi SA
• 14.3. Pharming Healthcare Inc.
• 14.4. Attune Pharmaceuticals
• 14.5. Adverum Biotechnologies
• 14.6. Arrowhead Pharmaceuticals
• 14.7. Ionis Pharmaceuticals
• 14.8. BioCryst Pharmaceuticals Inc.
• 14.9. CSL Behring.
• 14.10. CENTOGENE N.V.

15. Strategic Recommendations

16. About Us & Disclaimer